Table 1.
Demographic and clinical patients’ characteristics at baseline
| Patients (n = 454) | |
|---|---|
| Age (years) | |
| Median (q1-q3) | 77 (71-82) |
| ≥75 years, n (%) | 266 (58.6) |
| Gleason score ≥8 at tumor diagnosisa | 233 (59.0) |
| Metastasis at first prostate cancer diagnosis,bn (%) | 65 (14.3) |
| Time from first prostate cancer diagnosis to abiraterone (years), median (q1-q3) | 5.2 (2.2-9.3) |
| Time from castration to abiraterone (years), median (q1-q3) | 2.9 (1.1-6.0) |
| Time from mCRPC to abiraterone (months), median (q1-q3) | 1.6 (1.0-2.9) |
| PSA (ng/ml) at baseline, median (q1-q3) | 15.3 (5.0-44.1) |
| Location of metastases at baseline visit, n (%) | |
| Bone metastases only | 190 (41.9) |
| Lymph node metastasis only | 100 (22.0) |
| Bone + lymph node metastasis only | 103 (22.7) |
| At least one visceral metastasis | 38 (8.4) |
| Other | 23 (5.1) |
| No. of bone metastases at baseline visit,cn (%) | |
| 1-3 | 114 (39.6) |
| 4-9 | 111 (38.5) |
| ≥10 | 63 (21.9) |
| Not available | 32 |
| ECOG PS at baseline, n (%) | |
| 0 | 251 (56.8) |
| 1 | 168 (38.0) |
| ≥2 | 21 (4.8) |
| Not available | 12 |
| No. of comorbidities, n (%) | |
| 0 | 142 (31.3) |
| 1 | 139 (30.6) |
| ≥2 | 173 (38.1) |
| Type of comorbidity,dn (%) | |
| Cardiovascular disorders | 261 (57.5) |
| Hypertension | 221 (48.7) |
| History of myocardial infarction | 25 (5.5) |
| Arrhythmia | 20 (4.4) |
| Metabolic disorders | 105 (23.1) |
| Hypercholesterolemia | 52 (11.5) |
| Diabetes | 49 (10.8) |
| CNS disorders | 24 (5.3) |
| Renal disorders | 16 (3.5) |
| Hepatic disorders | 9 (2) |
| Other disorders | 94 (20.7) |
| Baseline FACT-P, median (q1-q3) | 110 (95-120) |
| Baseline EQ-5D-3L, median (q1-q3) | 0.9 (0.8-1.0) |
| EQ VAS, median (q1-q3) | 70 (50-80) |
| BPI item #3 (worst pain intensity) | |
| 0-1 | 195 (50.0) |
| 2-3 | 70 (17.9) |
| >3 | 125 (32.1) |
| Not available | 64 |
BPI, Brief Pain Inventory; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; EQ-5D-3L, European Quality of Life 5 Dimensions 3 Level; EQ VAS, European Quality of Life Visual Analog Scale; FACT-P, Functional Assessment of Cancer Therapy—Prostate; mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific antigen.
a
Information not available for 59 patients.
b
Information not available for nine patients.
c
Percentages were calculated over the number of patients with bone metastases.
d
Patient could have more than one medical condition.